ANCORA TECHNOLOGIES, INC. v. HTC AMERICA, INC.
Contributed by Knobbe Martens. Originally published on Patexia; republished here as part of the LexDana archive.
Federal Circuit Summary
Before Dyk, Wallach, and Taranto. Appeal from the United States District Court for the Western District of Washington
Summary: Claims directed to improving computer security by using BIOS memory to store a license can be a non-abstract computer-functionality improvement if done by a specific technique that departs from earlier approaches to solve a specific computer problem.
The district court granted HTC’s motion to dismiss, concluding that the claims are directed to, and ultimately claim no more than, an abstract idea using generic computer hardware for their intended purposes.
The Federal Circuit reversed, finding that the claims are not directed to ineligible subject matter, but to a solution to a computer-functionality problem under Enfish, LLC v. Microsoft Corp., 822 f .3d 1327 (Fed. Cir. 2016), and related authorities. The Court found that the claimed advance relies on specific and unique characteristics of certain aspects of the BIOS that the patent asserts were not previously used in the way now claimed, and the result is a beneficial reduction of the risk of hacking.
This case is: ANCORA TECHNOLOGIES, INC. v. HTC AMERICA, INC.
Edited by: Paul Stewart
Written by: Bryan J. Johnson and Karen M. Cassidy
More insights
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient with a Unit Dosage in Wyeth Llc v Astrazeneca Pharmaceuticals Lp
Written by : Eric Furman, Ph.D. and Ashley C. Morales Key Takeaway: Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal…
When About Becomes Indefinite Federal Circuit Provides Guidance for Life Science Patent Applications Regarding Limits of Approximation in Enviro Tech v Safe Foods
Written by : Jason J. Jardine and Kenneth O. Aruda, Ph.D. Key Takeaway: The term “about” remains useful in biotech and pharmaceutical claims, but only if the patent provides objective guidance about what the term means. Absent that guidance,…
When Any Patent Means No Patent Federal Circuit Reverses Non Specific Verdict
Written by : Brian C. Barnes and Sophia F. Zahn OLLNOVA TECHNOLOGIES LTD. v. ECOBEE TECHNOLOGIES ULC [OPINION] Before Chen , Cunningham, and Stark. Appeal from the United States District Court for the Eastern District of Texas. Summary : A verdict form…